Key result
Emerging positron emission tomography (PET) tracers, particularly those targeting fibroblast activation protein (FAP), show promise for the early, sensitive detection of subclinical cardiotoxicity.
Why the study?
Echocardiography is typically not sensitive to sub-clinical or early-stage cardiotoxicity, prompting the need to identify emerging PET tracers for detecting incipient cardiac damage.
Design
Review
Authors
Loading...
Echocardiography's limited sensitivity for subclinical cardiotoxicity warrants caution in monitoring; leaves open advanced imaging for early detection.
Emerging PET radiotracers offer a promising non-invasive approach to detect early, subclinical cardiotoxicity in cancer patients, potentially overcoming the sensitivity limitations of standard echocardiography.
Kelly et al. (2022) conducted a review in Cardiotoxicity. PET Tracers was evaluated. Emerging positron emission tomography (PET) tracers, particularly those targeting fibroblast activation protein (FAP), show promise for the early, sensitive detection of subclinical cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: